# US 11,439,621 B2 · Method of treating stimulant use disorder using a combination of topiramate and phentermine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,621 B2
- Document ID: US11439621B2
- Status: Granted
- Kind: B2
- Application number: 16/889,320
- Filed: 2020-06-01
- Published: 2020-12-03
- Granted: 2022-09-13
- Earliest claimed: 2019-05-31
- Assignees: University of Kentucky Research Foundation
- Applicants: University of Kentucky Research Foundation
- Inventors: Craig R. Rush
- Web page: https://patentgrep.com/patent/US11439621B2

## CPC

- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61P 25/30: for treating abuse or dependence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Combinations and methods for treating a subject experiencing or at risk of experiencing an undesired consequence of stimulant use are provided. The combinations include topiramate and phentermine. The methods include administering an effective dose of a combination of topiramate and phentermine to a subject. In some embodiments, the methods include administering an effective dose of a combination of topiramate and phentermine to a subject with cocaine use disorder.

## Claims

### Claim 1

A method of treating a subject who is experiencing or is at risk of experiencing an undesired consequence of cocaine use, the method comprising administering a combination of topiramate in a dose of 50 mg/day to 100 mg/day and phentermine in a dose of 15 mg/day to 30 mg/day to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the undesired consequence of cocaine use is craving for administration of a stimulant.

### Claim 3 (depends on 2)

The method of claim 2, wherein the stimulant is cocaine.

### Claim 4 (depends on 1)

The method of claim 1, wherein cocaine use includes cocaine misuse.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject is diagnosed with stimulant use disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject is diagnosed with cocaine use disorder.

### Claim 7 (depends on 1)

The method of claim 1, wherein administering the combination includes administering the topiramate in a dose of more than 50 mg/day.

### Claim 8 (depends on 1)

The method of claim 1, wherein administering the combination includes administering the topiramate in a dose of 100 mg/day.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering the combination includes administering the phentermine in a dose of more than 15 mg/day.

### Claim 10 (depends on 1)

The method of claim 1, wherein administering the combination includes administering the phentermine in a dose of 30 mg/day.

### Claim 11 (depends on 1)

The method of claim 1, wherein administering the combination includes administering the topiramate in a dose of 100 mg/day and administering the phentermine in a dose of 30 mg/day.

### Claim 12 (depends on 1)

The method of claim 1, wherein administering the combination comprises administering the combination as a composition that includes both the topiramate and the phentermine.

### Claim 13

A method for treating cocaine use disorder, the method comprising administering an effective dose of a combination of topiramate in a dose of 50 mg/day to 100 mg/day and phentermine in a dose of 15 mg/day to 30 mg/day to a subject with cocaine use disorder.

### Claim 14 (depends on 13)

The method of claim 13, wherein administering the combination includes administering the topiramate in a dose of more than 50 mg/day.

### Claim 15 (depends on 13)

The method of claim 13, wherein administering the combination includes administering the phentermine in a dose of more than 15 mg/day.

### Claim 16 (depends on 13)

The method of claim 13, wherein administering the combination includes administering the phentermine in a dose of 30 mg/day.

### Claim 17 (depends on 13)

The method of claim 13, wherein administering the combination includes administering the topiramate in a dose of 100 mg/day and administering the phentermine in a dose of 30 mg/day.

### Claim 18 (depends on 13)

The method of claim 13, wherein administering the combination includes administering topiramate in a dose of 100 mg/day.